Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders

IF 9.2 1区医学 Q1 IMMUNOLOGY

Autoimmunity reviews Pub Date : 2025-01-20 DOI:10.1016/j.autrev.2025.103754

Franz Felix Konen , Nora Möhn , Torsten Witte , Matthias Schefzyk , Miriam Wiestler , Svjetlana Lovric , Karsten Hufendiek , Konstantin Fritz Jendretzky , Stefan Gingele , Philipp Schwenkenbecher , Kurt-Wolfram Sühs , Manuel A. Friese , Luisa Klotz , Refik Pul , Marc Pawlitzki , David Hagin , Christoph Kleinschnitz , Sven G. Meuth , Thomas Skripuletz

{"title":"Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders","authors":"Franz Felix Konen , Nora Möhn , Torsten Witte , Matthias Schefzyk , Miriam Wiestler , Svjetlana Lovric , Karsten Hufendiek , Konstantin Fritz Jendretzky , Stefan Gingele , Philipp Schwenkenbecher , Kurt-Wolfram Sühs , Manuel A. Friese , Luisa Klotz , Refik Pul , Marc Pawlitzki , David Hagin , Christoph Kleinschnitz , Sven G. Meuth , Thomas Skripuletz","doi":"10.1016/j.autrev.2025.103754","DOIUrl":null,"url":null,"abstract":"<div><div>A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological processes underlying MS, the exploration of additional medical compounds within clinical trials has been ignited. Emerging novel medications with innovative mechanisms of action are being introduced. Those mechanisms of action include a broad therapeutic spectrum of substances targeting various protein kinases, some of which could also be used for the treatment of other autoimmune-mediated diseases. The advancement of new compounds could therefore enable a more personalized approach in treating MS, taking into consideration patients' co-existing autoimmune-mediated diseases. In this review, we discuss potential compounds targeting protein kinases, currently under investigation in clinical trials for various autoimmune diseases that could become viable treatment options for MS and comorbid autoimmune conditions in the future.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 4","pages":"Article 103754"},"PeriodicalIF":9.2000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autoimmunity reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S156899722500014X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological processes underlying MS, the exploration of additional medical compounds within clinical trials has been ignited. Emerging novel medications with innovative mechanisms of action are being introduced. Those mechanisms of action include a broad therapeutic spectrum of substances targeting various protein kinases, some of which could also be used for the treatment of other autoimmune-mediated diseases. The advancement of new compounds could therefore enable a more personalized approach in treating MS, taking into consideration patients' co-existing autoimmune-mediated diseases. In this review, we discuss potential compounds targeting protein kinases, currently under investigation in clinical trials for various autoimmune diseases that could become viable treatment options for MS and comorbid autoimmune conditions in the future.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Autoimmunity reviews 医学-免疫学

CiteScore

24.70

自引率

4.40%

发文量

164

审稿时长

21 days

期刊介绍： Autoimmunity Reviews is a publication that features up-to-date, structured reviews on various topics in the field of autoimmunity. These reviews are written by renowned experts and include demonstrative illustrations and tables. Each article will have a clear "take-home" message for readers. The selection of articles is primarily done by the Editors-in-Chief, based on recommendations from the international Editorial Board. The topics covered in the articles span all areas of autoimmunology, aiming to bridge the gap between basic and clinical sciences. In terms of content, the contributions in basic sciences delve into the pathophysiology and mechanisms of autoimmune disorders, as well as genomics and proteomics. On the other hand, clinical contributions focus on diseases related to autoimmunity, novel therapies, and clinical associations. Autoimmunity Reviews is internationally recognized, and its articles are indexed and abstracted in prestigious databases such as PubMed/Medline, Science Citation Index Expanded, Biosciences Information Services, and Chemical Abstracts.